3-氨基-5-(2-氯苯基)噻吩-2-羧酸甲酯 | 107818-29-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 3-氨基-5-(2-氯苯基)噻吩-2-羧酸甲酯
• 英文名称: Methyl 3-amino-5-(2-chlorophenyl)thiophene-2-carboxylate
• CAS: 107818-29-1
• 化学式: C₁₂H₁₀ClNO₂S
• mdl: MFCD11207952
• 分子量: 267.736
• InChiKey: YIQJFQMRWXPBSJ-UHFFFAOYSA-N

物化性质

• 沸点：
  449.5±45.0 °C(Predicted)
• 密度：
  1.363±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  80.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-氨基-5-(2-氯苯基)噻吩-2-羧酸甲酯 在 sodium hydroxide 、 氯化亚砜 作用下， 以 甲醇 为溶剂， 生成 3-Amino-5-(2-chloro-phenyl)-thiophene-2-carbonyl chloride
  参考文献：
  名称：

  Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors

  摘要：

  A hit-to-lead optimisation programme was carried out on the thiophenecarboxamide high throughput screening hits 1 and 2 resulting in the discovery of the potent and orally bioavailable IKK-2 inhibitor 22. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.058
• 作为产物：
  描述：

  邻氯苯乙酮 在 sodium methylate 、 三氯氧磷 作用下， 以 甲醇 为溶剂， 反应 2.17h， 生成 3-氨基-5-(2-氯苯基)噻吩-2-羧酸甲酯
  参考文献：
  名称：

  The discovery and optimization of pyrimidinone-containing MCH R1 antagonists

  摘要：

  Optimization of a series of constrained melanin-concentrating hormone receptor 1 (MCH RI) antagonists has provided compounds with potent and selective MCH R1 activity. Details of the optimization process are provided and the use of one of the compounds in an animal model of diet-induced obesity is presented. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.07.008

文献信息

• Novel Compounds
  申请人：——

  公开号：US20020107252A1

  公开（公告）日：2002-08-08

  The invention relates to heteroaromatic carboxamides of formula (I), 1 wherein A, R 1 , R 2 and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

  这项发明涉及到式(I)的杂环芳香族羧酰胺， 其中A、R1、R2和X如规范中定义，以及用于它们制备的过程和中间体，含有它们的药物组合物以及它们在治疗中的应用。
• [EN] HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2<br/>[FR] DERIVES DE CARBOXAMIDES HETEROAROMATIQUES ET LEUR UTILISATION COMME INHIBITEURS DE L'ENZYME IKK-2
  申请人：ASTRAZENECA AB

  公开号：WO2001058890A1

  公开（公告）日：2001-08-16

  The invention relates to heteroaromatic carboxamides of formula (I), wherein A, R1, R2 and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明涉及式（I）的杂环芳香族羧酰胺，其中A，R1，R2和X如规范中定义的过程和中间体，制备它们所用的制剂，含有它们的制药组合物以及它们在治疗中的使用。
• Substituted thiophene compounds
  申请人：Baxter Andrew

  公开号：US20090181962A1

  公开（公告）日：2009-07-16

  The invention relates to heteroaromatic carboxamides of formula (I), wherein A, R 1 , R 2 , and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明涉及公式（I）的杂环芳香族羧酰胺，其中A，R1，R2和X如规范中所定义，以及用于它们的制备的过程和中间体，包含它们的制药组合物以及它们在治疗中的使用。
• Potent, Selective, and Orally Efficacious Antagonists of Melanin-Concentrating Hormone Receptor 1
  作者：Francis X. Tavares、Kamal A. Al-Barazanji、Eric C. Bigham、Michael J. Bishop、Christy S. Britt、David L. Carlton、Paul L. Feldman、Aaron S. Goetz、Mary K. Grizzle、Yu C. Guo、Anthony L. Handlon、Donald L. Hertzog、Diane M. Ignar、Daniel G. Lang、Ronda J. Ott、Andrew J. Peat、Hui-Qiang Zhou

  DOI：10.1021/jm060572f

  日期：2006.11.30

  The high expression of MCH in the hypothalamus with the lean hypophagic phenotype coupled with increased resting metabolic rate and resistance to high fat diet-induced obesity of MCH KO mice has spurred considerable efforts to develop small molecule MCHR1 antagonists. Starting from a lead thienopyrimidinone series, structure-activity studies at the 3- and 6-positions of the thienopyrimidinone core afforded potent and selective MCHR1 antagonists with representative examples having suitable pharmacokinetic properties. Based on structure-activity relationships, a structural model for MCHR1 was constructed to explain the binding mode of these antagonists. In general, a good correlation was observed between pK(a)s and activity in the right-hand side of the template, with Asp123 playing an important role in the enhancement of binding affinity. A representative example when evaluated chronically in diet-induced obese mice resulted in good weight loss effects. These antagonists provide a viable lead series in the discovery of new therapies for the treatment of obesity.
• HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2
  申请人：AstraZeneca AB

  公开号：EP1261600A1

  公开（公告）日：2002-12-04